Our science

Publications and presentations

Filter content:

X-Linked Retinitis Pigmentosa

Subretinal Gene Therapy Laru-zova (AGTC-501) for X-linked Retinitis Pigmentosa (XLRP): Phase 2 DAWN Safety and Efficacy Update

7 May 2026

Subretinal Gene Therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 1/2 HORIZON 5- year Safety Results

7 May 2026

Subretinal laru-zova Gene Therapy for XLRP: Phase 2 SKYLINE Trial Post-Hoc Microperimetry Scotomatous vs. Nonscotomatous Analysis

7 May 2026

Subretinal Gene Therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Pivotal Phase 2/3 VISTA Trial Design and Baseline Demographics

7 May 2026

Subretinal Gene Therapy laru-zova for X-linked Retinitis Pigmentosa (XLRP): Phase 2 DAWN Trial, Preliminary Month 9+ Results

4 September 2025

Subretinal laru-zova Gene Therapy for XLRP: 36-Month Results of the Randomized, Controlled, Multicenter Phase 2 SKYLINE Trial

4 September 2025

Subretinal Gene Therapy laru-zova (AGTC-501) for X-linked Retinitis Pigmentosa (XLRP): Phase 2 DAWN Preliminary Month 6+ Results

6 May 2025

Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results – American Journal of Ophthalmology

26 March 2025

RPGR gene therapy and the Beacon clinical trials: Beacon Therapeutics Subretinal Gene Therapy laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP)

7 December 2024

Subretinal Gene Therapy laru-zova (AGTC-501) for X-Linked Retinitis Pigmentosa (XLRP) Phase 2 Multicenter Study (DAWN): Preliminary Results

6 December 2024

Geographic Atrophy

Development of BTX-001, a novel AAV-Mediated Intravitreal Gene Therapy Delivering a C5 Inhibitor for Geographic Atrophy

7 May 2026